The purpose of this research study is to find the best dose of the study drug (PF-04136309) in combination with FOLFIRINOX as well as to see what the side effects of this treatment regimen are. PF-04136309 is considered investigational, which means that it has not been approved by the U.S. Food and Drug Administration (FDA). FOLFIRINOX is a combination of several drugs that are given
together the same way every time: 5FU, leucovorin, irinotecan, and oxaliplatin. This combination of drugs is supported by the National Comprehensive Cancer Network for use in patients with pancreas cancer that cannot be removed surgically. It has not, however, been approved by the FDA.
|
|
More Information:
|